Semaglutide Dosing and Titration: The 0.25 to 2.4 mg Schedule Explained

Nearly every question a person types about semaglutide dosing, whether it is about the starting dose, the "titration schedule," dosing in units, or the max dose, traces back to one design choice built into its pivotal weight-management trial: the dose was raised in four-week steps rather than started at the target. The 2.4 mg figure most associated with semaglutide's results was a destination reached across the first four months of a 68-week protocol, not a day-one dose. ^[1]

This post reports how that schedule was structured, why it exists, how it compares with the oral formulations, and how it is reconstituted and measured, all attributed to the published trial and labeling literature. None of it is medical advice, and these are research compounds.

The standard semaglutide titration schedule

The pivotal Phase 3 weight-management trial (STEP 1, Wilding et al., New England Journal of Medicine, 2021) randomized adults with overweight or obesity to once-weekly subcutaneous semaglutide or placebo for 68 weeks. Participants assigned to semaglutide did not begin at 2.4 mg. The dose was escalated in a fixed stepwise sequence, roughly every four weeks, before reaching the maintenance dose. ^[1]

The shape is orderly: five fixed steps, four weeks apiece, ending at a maintenance dose held for the remainder of the trial. ^[1] The placebo arm lost a mean of 2.4 percent of body weight over the same 68 weeks, which puts the treatment effect of the full escalation-to-maintenance protocol at roughly 12.5 percentage points. ^[1] This is reported trial protocol, described here as information, not a schedule to follow.

What was semaglutide's starting dose?

The most common misconception is that semaglutide "is a 2.4 mg drug." It is not. The trial protocol and the approved weight-management label both begin at 0.25 mg once weekly, a dose too low to be expected to drive meaningful weight loss on its own. ^[1] Its job is priming, not efficacy.

That low start exists because the same GLP-1 receptor activity that suppresses appetite also slows gastric emptying, and a large abrupt change in that signal is what produces nausea. Starting at the target dose would front-load the sharpest possible change in exposure. The trial's design answer was to make the opening month deliberately sub-therapeutic and let the dose build from there. The complete semaglutide guide covers how this dosing design fits the broader efficacy and safety picture.

Why titration reduces GI side effects

The gastrointestinal effects reported across the semaglutide weight-management program (nausea, diarrhea, vomiting, constipation) were more frequent during the escalation phase and eased once a dose was held steady. ^[1] That timing follows directly from the mechanism rather than being incidental.

GLP-1 receptor agonism slows gastric emptying as part of how it suppresses appetite. Applied too abruptly, that same slowing is what produces nausea. So the weeks of fastest change in exposure, the step-up weeks, are also the weeks of worst tolerability. Hold the dose steady for a few weeks and the system adapts. ^[1]

There is a pharmacokinetic layer underneath the tolerability pattern. Semaglutide's half-life is approximately 7 days, engineered through a fatty-diacid side chain that binds the molecule to serum albumin and shields it from rapid enzymatic breakdown. ^[5] Because of that long half-life, each dose step keeps accumulating toward a new steady state for several weeks rather than taking effect immediately. Spacing the steps four weeks apart gives each level time to approach its own plateau before the next increase stacks on top of it.

Weekly cadence and the half-life rationale

Semaglutide is dosed once weekly by subcutaneous injection in its approved weight-management form, and that interval follows directly from its pharmacokinetics. Native GLP-1 has a half-life measured in minutes; semaglutide's fatty-diacid albumin-binding modification and its resistance to DPP-4 breakdown extend that to roughly a week. ^[5] A seven-day dosing interval keeps plasma levels from swinging widely between injections.

The practical consequence is that dosing cadence and biological effect run on different clocks. A weekly injection sets the rhythm, but exposure at any dose level keeps building toward steady state for multiple weeks, and the STEP 1 trial measured its weight-loss endpoint at 68 weeks, long after any individual injection. ^[1] Weekly is the schedule; months is the timescale that matters.

Maintenance dose versus continued escalation

A recurring question is whether 2.4 mg is a ceiling to hold indefinitely or a step toward something higher. In the STEP 1 design, 2.4 mg was the endpoint: participants escalated through the four lower steps and then held at 2.4 mg for the remainder of the 68-week trial. ^[1] There was no further planned increase built into the protocol beyond that maintenance level.

That distinction, escalation phase versus maintenance phase, lines up with the side-effect pattern already described. The escalation phase is where tolerability is tested; the maintenance phase is the long stretch where the weight-loss curve did its steepest cumulative work toward the 14.9 percent endpoint. ^[1] The dosing design treats the maintenance dose as a level to stay at long enough for the effect to express, not a number to keep climbing past.

What is semaglutide's maximum dose?

In the approved weight-management protocol, 2.4 mg once weekly is the highest dose studied and the maintenance dose associated with the largest mean weight loss in STEP 1. ^[1] A separate consideration applies to the oral formulations, covered below, which use an entirely different dose range because absorption through the gut is far less efficient than a subcutaneous injection.

Semaglutide dosing in units and reconstitution

Retail semaglutide pens are pre-filled and dosed directly in milligrams, but a research vial ships as either a solution or a lyophilized powder that must be reconstituted with bacteriostatic water before it can be measured. The concentration created (milligrams of peptide divided by milliliters of water added) is what turns a milligram figure into a number of "units" on an insulin syringe. This is arithmetic, not a recommendation.

The logic mirrors any peptide reconstitution: a U-100 insulin syringe reads 100 units per 1 mL. If a 2 mg vial is dissolved into 1 mL of water, the whole vial spans 100 units and 2 mg, so 0.25 mg works out to 12.5 units. Add 2 mL instead and the same vial spans 200 units of volume, doubling the units-per-mg ratio. The peptide mass never changes, only the units-to-mg conversion, which is set entirely at reconstitution. This is why "semaglutide units to mg" has no single answer without knowing the concentration. The general handling steps, sanitizing the stopper, adding water slowly down the vial wall, swirling rather than shaking, and refrigerated storage, are covered in how to reconstitute peptides with bacteriostatic water.

How does oral semaglutide dosing differ?

Oral semaglutide dosing follows a different schedule than the weekly injection because the peptide has to survive the stomach, which requires a much higher dose and a co-formulated absorption enhancer. The originally approved daily oral formulation, developed for glycemic control, titrates from 3 mg once daily for the first 30 days, to 7 mg once daily, with an optional increase to 14 mg once daily if additional glycemic control is needed. ^[4]

A separate, higher-dose oral formulation has been studied specifically for weight management. Its Phase 3 trial (OASIS 1, Knop et al., The Lancet, 2023) titrated participants up through intermediate doses to a top dose of 50 mg once daily and reported a mean 15.1 percent body-weight loss at 68 weeks, a result in the same range as the injectable STEP 1 outcome. ^[3] The two oral products, the original glycemic-control formulation and the higher-dose weight-management formulation, are titrated differently from each other and from the weekly injection, so "oral semaglutide dose" only has a single answer once the specific product and indication are specified.

Missed-dose handling and the half-life buffer

Because weekly cadence and a roughly 7-day half-life are closely matched, the pharmacokinetics build in some tolerance for a missed dose. The approved prescribing information for the weekly injection states that a missed dose can still be taken if fewer than 5 days have passed since the scheduled day; if more than 5 days have passed, the missed dose is skipped and the regular weekly schedule resumes on the next scheduled day. ^[2] This is labeling guidance reported as information, not a personal instruction.

The structural reason this window exists is the same half-life that permits once-weekly dosing in the first place. A compound with a multi-day half-life degrades gradually rather than falling off a cliff, so a short delay changes exposure only modestly. ^[5] A protocol built on a long-half-life molecule behaves very differently from one built on a short-acting molecule, where a missed dose creates a true gap in exposure.

Common semaglutide dosing mistakes

• Treating 2.4 mg as a starting dose: it is the top of a five-step schedule reached after 16 weeks, never a day-one dose in the pivotal trial. ^[1]
• Rushing the four-week holds: the gradual ramp exists specifically to manage GI tolerability, and compressing the step durations is a common reason a protocol is abandoned during escalation. ^[1]
• Judging results in the first month: with a roughly 7-day half-life, a new dose level keeps building toward its own steady state for several weeks, so the earliest weeks at any step systematically understate it. ^[5]
• Confusing "units" with a fixed milligram dose: units are a volume readout, and how many units equal a milligram depends entirely on the concentration set at reconstitution.
• Mixing up the oral and injectable dose ranges: the daily oral formulations (3 to 14 mg, or up to 50 mg for the weight-management oral product) use entirely different numbers than the once-weekly injection (0.25 to 2.4 mg), because oral absorption is far less efficient. ^{[3] [4]}
• Skipping the missed-dose window rule: the label's 5-day cutoff for taking a missed dose late is a specific, defined rule, not a general "whenever you remember" allowance. ^[2]

For research and educational purposes only. Not medical advice. All doses, titration schedules, and trial figures describe published clinical studies and approved product labeling, reported here as information, not as personal dosing instructions. These compounds are for research use.